Global Cancer Diagnostics Market Major Players 2024, Forecast To 2033
9 Jan, 2024
The cancer diagnostics market has undergone rapid growth, increasing from $21.38 billion in 2023 to $23.84 billion in 2024, with a significant CAGR of 11.5%. Historical growth is linked to rising cancer incidence, screening programs, and personalized medicine. Future growth, projected at $37.09 billion in 2028, will be driven by emerging markets, AI, early detection, and intervention.
Global Cancer Diagnostics Market Key Driver
The cancer diagnostics market is propelled by a high prevalence rate of various cancers, leading to increased demand for diagnosis and treatment. Cancer ranks as the second-leading cause of death globally, with an estimated 23.6 million new cases per year by 2030, according to the National Cancer Institute (NCI).
Get A Free Sample Of The Global Cancer Diagnostics Market ReportGlobal Cancer Diagnostics Market Segments
The cancer diagnostics market covered in this report is segmented –
1) By Products: Companion Diagnostics, Molecular Diagnostics
2) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging
3) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications
4) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users
By Geography: The regions covered in the cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the cancer diagnostics market in 2023. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Cancer Diagnostics Industry Players
Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Elekta AB, C.R. BardInc., Biogenex Laboratories, Eckert & Ziegler BEBIG, Veracyte, PathAI, Bio-Rad Laboratories, Biochain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Eli Lilly and Co, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, IBA group, Invitae Corporation, Medtronic plc, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics, Theragenics Corporation, Varian Medical SystemsInc.
Get The Full Global Cancer Diagnostics Market Report
Cancer Diagnostics Market Overview
Cancer diagnostic devices refer to medical equipment used to detect and diagnose the stage and cause of the condition by identifying the oncogenic proteins, and certain enzymes released by the tumor cells in patients.
Cancer Diagnostics Global Market Report 2023 provides data on the global cancer diagnostics market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The cancer diagnostics market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.